Provided by Tiger Trade Technology Pte. Ltd.

ImmunityBio, Inc.

10.29
+1.0110.83%
Post-market: 10.340.0550+0.53%18:22 EDT
Volume:31.20M
Turnover:319.10M
Market Cap:10.90B
PE:-10.40
High:10.55
Open:9.39
Low:9.39
Close:9.28
52wk High:12.43
52wk Low:1.95
Shares:1.06B
Float Shares:407.00M
Volume Ratio:2.43
T/O Rate:7.66%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9887
EPS(LYR):-0.3820
ROE:78.05%
ROA:-30.54%
PB:-10.41
PE(LYR):-26.92

Loading ...

Movement Alert|ImmunityBio Rises 5.65% in Regular Trading, Rebounds After Digesting FDA Warning Letter Pressure

Market Focus
·
Jun 17

Movement Alert|ImmunityBio Falls 5.12% in Regular Trading, FDA Warning Letter Continues to Suppress Market Confidence

Market Focus
·
Jun 17

ImmunityBio shareholders re-elect nine directors at annual meeting

Reuters
·
Jun 11

3 Growth Companies With High Insider Ownership Seeing Up To 94% Earnings Growth

Simply Wall St.
·
Jun 09

Movement Alert|ImmunityBio Rises 5.06% in Regular Trading, ASCO Clinical Data and Guideline Inclusion Fuel Rebound

Market Focus
·
Jun 09

ImmunityBio director Barry J. Simon sells 23,033 common shares worth $165,284

Reuters
·
Jun 06

Movement Alert|ImmunityBio Falls 5.01% in Regular Trading, Sustained Profit-Taking Pressure After Multiple Catalysts Realized

Market Focus
·
Jun 06

ImmunityBio (IBRX) Is Down 5.6% After New Phase 3 ANKTIVA Lung Cancer Data Release – Has The Bull Case Changed?

Simply Wall St.
·
Jun 05

ImmunityBio Advances HPV-Positive Head and Neck Cancer Trial, Setting Up a New Catalyst for IBRX Investors

TIPRANKS
·
Jun 05

ImmunityBio Price Target Maintained With a $15.00/Share by HC Wainwright & Co.

Dow Jones
·
Jun 02

ImmunityBio presents Phase 3 lung cancer data on ANKTIVA-based regimen at ASCO 2026

Reuters
·
Jun 02

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jun 01

Movement Alert|ImmunityBio Falls 5.12% in Regular Trading, Technical Rebound Fades as Profit-Taking Resumes After Multiple Catalysts Priced In

Market Focus
·
May 29

How FDA Review of ANKTIVA Bladder Cancer sBLA Could Impact ImmunityBio (IBRX) Investors

Simply Wall St.
·
May 29

Movement Alert|ImmunityBio Rises 5.66% in Regular Trading, AUA Positive Efficacy Data Fuels Rebound After Two-Day Selloff

Market Focus
·
May 26

Movement Alert|ImmunityBio Falls 5.23% in Regular Trading, Profit-Taking Continues After Multiple Catalysts Priced In

Market Focus
·
May 22

ImmunityBio survey shows UK NMIBC patients favor bladder-sparing therapy after BCG failure

Reuters
·
May 22

ImmunityBio says ANKTIVA plus BCG shows lower cost per sustained responder vs TAR-200

Reuters
·
May 22

Is ANKTIVA’s BCG Tie-Up And New Patents Altering The Investment Case For ImmunityBio (IBRX)?

Simply Wall St.
·
May 21

Movement Alert|ImmunityBio Falls 7.89% in Regular Trading, Profit-Taking Emerges After Multiple Catalysts Priced In

Market Focus
·
May 21